Skip to main content
Alberto Espay, MD, Neurology, Cincinnati, OH

AlbertoEspayMDMSc

Neurology Cincinnati, OH

Movement Disorder

Professor of Neurology Director and Endowed Chair, James J. and Joan A. Gardner Center for Parkinson’s Disease and Movement Disorders University of Cincinnati 

Dr. Espay is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Espay's full profile

Already have an account?

  • Office

    222 Piedmont Avenue
    Ste. 3100
    Cincinnati, OH 45219
    Phone+1 513-475-8730
    Fax+1 513-475-8033

Summary

  • Dr. Alberto Espay is Professor and Endowed Chair of the James J. and Joan A. Gardner Center for Parkinson’s disease at the University of Cincinnati. He has published over 300 peer-reviewed research articles and 8 books, including Common Movement Disorders Pitfalls, which received the Highly Commended BMA Medical Book Award in 2013 and Brain Fables, the Hidden History of Neurodegenerative Diseases and a Blueprint to Conquer them, coauthored with Parkinson patient and advocate Benjamin Stecher, selected by the Association of American Publishers for the PROSE Award honoring the best scholarly work in Neuroscience published in 2020. He has served as Chair of the Movement Disorders Section of the American Academy of Neurology, Associate Editor of the Movement Disorders journal, and on the Executive Committee of the Parkinson Study Group. Among other honors, he has received the Cincinnati Business Courier’s Health Care Hero award, the Spanish Society of Neurology’s Cotzias award, and honorary membership in the Mexican Academy of Neurology. He currently serves as President-Elect of the Pan-American Section of the International Parkinson and Movement Disorders Society. With colleagues at the University of Cincinnati, he recently launched the first biomarker study of aging (CCBPstudy.com), designed to match people with neurodegenerative disorders to available therapies from which they are most biologically suitable to benefit, regardless of their clinical diagnoses.

Education & Training

  • University of Toronto
    University of TorontoM.Sc., Clinical Epidemiology and Health Care Research, 2003 - 2005
  • Indiana University School of Medicine
    Indiana University School of MedicineResidency, Neurology, 1998 - 2001
  • Ascension St Vincent Hospital Indianapolis
    Ascension St Vincent Hospital IndianapolisInternship, Transitional Year, 1997 - 1998
  • Central University of Venezuela
    Central University of VenezuelaClass of 1994
  • Liceo de Aplicacion
    Liceo de AplicacionB.S., 1987

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2005 - 2025
  • NY State Medical License
    NY State Medical License 2002 - 2005
  • NM State Medical License
    NM State Medical License 1996 - 1996
  • American Board of Psychiatry and Neurology Neurology
  • National Board of Physicians and Surgeons Neurology

Awards, Honors, & Recognition

  • Top Doctor Cincinnati Magazine, 2014
  • Fellow American Academy of Neurology (FAAN), 2013
  • Fellow American Neurological Association (FANA), 2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Levodopa‐Induced Dyskinesia in Parkinson Disease: Current and Evolving Concepts  
    Aristide Merola, Alberto J Espay, Annals of Neurology
  • Impaired Emotion Processing in Functional (Psychogenic) Tremor: A Functional Magnetic Resonance Imaging Study  
    Thomas Maloney, Alberto J Espay, Jerzy P Szaflarski, ScienceDirect
  • Double-Blind, Double-Dummy, Study of Continuous Intrajejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease  
    Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Ohtman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Anton..., Lancet Neurol, 12/19/2013
  • Join now to see all

Press Mentions

  • Ozempic Linked to Lower Alzheimer's Risk in People with Type 2 Diabetes
    Ozempic Linked to Lower Alzheimer's Risk in People with Type 2 DiabetesOctober 24th, 2024
  • What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trials
    What Drugmakers Did Not Tell Volunteers in Alzheimer’s TrialsOctober 23rd, 2024
  • New Study Challenges Amyloid-Beta Theory on Cause for Alzheimer's Disease
    New Study Challenges Amyloid-Beta Theory on Cause for Alzheimer's DiseaseSeptember 18th, 2024
  • Join now to see all

Professional Memberships

Other Languages

  • Spanish, Italian